Cambridge Nutritional Sciences plc (CNSL) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Cambridge Nutritional Sciences plc £0.02, price £0.02, upside +31.0%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cambridge Nutritional Sciences plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range £0.0140 – £0.5800 · fair‑value band £0.0203 – £0.0233 · the £0.0155 price screens below the £0.0203 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Cambridge Nutritional Sciences in your weekly email
Every Wednesday you see whether Cambridge Nutritional Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand.
Show more
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand. It also provides clinical analysis to the general public, clinics, and health professionals; and supplies Food Detective, a food sensitivity test. In addition, the company offers My Health Tracker, a health app for tracking symptoms, accessing FoodPrint results, and managing gut health; and CNS Lab, which provides laboratory services for food sensitivity. It serves the government, private hospitals and clinics, reference laboratories, nutritionists, naturopaths, consumers, and functional medicine healthcare practitioners in the United Kingdom, rest of Europe, North America, South/Central America, India, rest of Asia and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc is based in London, the United Kingdom.
Stock analysis
Cambridge Nutritional Sciences plc (CNSL) currently trades at £0.0155, while our model-based Fair Value estimate is £0.0203, implying the stock looks roughly 23.6% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £0.1300 per share, and 8 of the 8 models we run sit above the £0.0155 price.
Bear case: the Asset-Based group reads lowest at £0.0300, and 0 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: £0.0203 (bear) to £0.0233 (bull), the price of £0.0155 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Cambridge Nutritional Sciences plc reported revenue of £8.3M in FY2025 versus £6.8M in FY2021, a compound +5.1%/yr. Reported net income was £1.6M in FY2025.
Key figures
Market cap 4.1M GBX · P/E ratio 1.6 · P/S ratio 0.29 · EPS (TTM) £0.0100 · Net margin 18.8% · Return on equity 13.3% · Return on assets (EBIT) −6.5% · Operating margin −7.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 31%, CNSL screens cheaper than that median.
Fair Value models
Bear £0.0203Fair Value £0.0203Bull £0.0233
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (£0.0100 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Start year 2020 (pandemic). Over 10 years: −3.7% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−2.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3% vs 0%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−82% → −8%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 10.8%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Cambridge Nutritional Sciences plc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+35% · Top 25%
Profitability
Return on equity (TTM)13% · Top 25%
Return on assets−3% · Bottom 25%
Net margin (TTM)17% · Top 25%
Operating margin (TTM)−8% · Bottom 25%
Growth and dividend
Revenue growth−7% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cambridge Nutritional Sciences plc (CNSL) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of £0.0203 versus a price of £0.0155, about +31% upside (undervalued).
What is the fair value of CNSL?
Our model-based fair value for Cambridge Nutritional Sciences plc is £0.0203 (as of Sep 23, 2026), built from audited fundamentals. The current price: £0.0155.
What is the quality score of CNSL?
Cambridge Nutritional Sciences plc has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cambridge Nutritional Sciences plc (CNSL)?
Our model-based price target is the fair value of £0.0203 (as of Sep 23, 2026) from 8 valuation models. Cautious scenario £0.0203, optimistic scenario £0.0233. It is a calculation from audited fundamentals, not an analyst target.
What is the Cambridge Nutritional Sciences plc stock forecast for 2026?
Our models put fair value at £0.0203, about +31% upside versus a price of £0.0155 (undervalued). Cautious scenario £0.0203, optimistic scenario £0.0233. The calculation is refreshed regularly with new filings.
What is the revenue of Cambridge Nutritional Sciences plc (CNSL)?
Cambridge Nutritional Sciences plc reported trailing-twelve-month revenue of about £8.1M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Cambridge Nutritional Sciences plc (CNSL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cambridge Nutritional Sciences plc it is £0.0203 per share (as of Sep 23, 2026), against a price of £0.0155. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Cambridge Nutritional Sciences plc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CNSL trades below its calculated fair value: price £0.0155, fair value £0.0203, a gap of about +31% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CNSL?
No. The price is what the market pays today (£0.0155); the fair value is what the company's own numbers justify (£0.0203). For Cambridge Nutritional Sciences plc the two are £0.0048 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cambridge Nutritional Sciences plc worth?
The market values Cambridge Nutritional Sciences plc at about 4.1M GBX (market capitalisation, as of Sep 23, 2026). Per share that is £0.0155; our models calculate a fair value of £0.0203 per share.
What do the bullish and bearish scenarios say about CNSL?
Our models span a range for Cambridge Nutritional Sciences plc: cautious scenario £0.0203, base £0.0203, optimistic £0.0233 per share (as of Sep 23, 2026, price £0.0155). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CNSL?
Cambridge Nutritional Sciences plc trades at a price-to-earnings ratio of 1.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £0.0203 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.7.
How solid is the balance sheet of Cambridge Nutritional Sciences plc (CNSL)?
Balance-sheet figures for Cambridge Nutritional Sciences plc (as of Sep 23, 2026): return on equity 13.3%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is CNSL from its 52-week high?
Cambridge Nutritional Sciences plc trades at £0.0155, about 49% below its 52-week high of £0.0305 and 11% above the low of £0.0140 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0203 is for.
Which stocks are comparable to Cambridge Nutritional Sciences plc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cambridge Nutritional Sciences plc stock attractive at the current price?
The data as of Sep 23, 2026: price £0.0155, calculated fair value £0.0203 (+31%), Quality Score 52/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CNSL calculated?
We run Cambridge Nutritional Sciences plc through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.0203, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Cambridge Nutritional Sciences plc currently trades 31 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cambridge Nutritional Sciences plc (CNSL)?
The closing price on Sep 24, 2026 was £0.0155. Our model-based fair value is £0.0203, about +31% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cambridge Nutritional Sciences plc right now?
The price is below even our cautious bear case (£0.0203). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality. The models converge in a tight band (£0.0203 to £0.0233), unusually little disagreement for a valuation.
Key figures of Cambridge Nutritional Sciences plc
How large is the market capitalisation of Cambridge Nutritional Sciences plc (CNSL)?
The market capitalisation of Cambridge Nutritional Sciences plc is 4.1M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cambridge Nutritional Sciences plc (CNSL)?
The price-to-sales ratio of Cambridge Nutritional Sciences plc is 0.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cambridge Nutritional Sciences plc (CNSL)?
Earnings per share at Cambridge Nutritional Sciences plc are £0.0100 (price ÷ EPS = P/E 1.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cambridge Nutritional Sciences plc (CNSL)?
The net margin of Cambridge Nutritional Sciences plc is 18.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cambridge Nutritional Sciences plc (CNSL)?
The return on equity (ROE) of Cambridge Nutritional Sciences plc is 13.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cambridge Nutritional Sciences plc (CNSL)?
On an EBIT basis the return on assets of Cambridge Nutritional Sciences plc is −6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cambridge Nutritional Sciences plc (CNSL)?
The operating margin of Cambridge Nutritional Sciences plc is −7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cambridge Nutritional Sciences plc (CNSL)?
Revenue at Cambridge Nutritional Sciences plc is growing −6.6% versus a year earlier (3y avg −0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cambridge Nutritional Sciences plc (CNSL)?
Earnings per share at Cambridge Nutritional Sciences plc are growing +376% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cambridge Nutritional Sciences plc (CNSL) generate?
The free cash flow of Cambridge Nutritional Sciences plc is −142K GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cambridge Nutritional Sciences plc (CNSL) hold?
Cambridge Nutritional Sciences plc holds more cash than debt, 4.5M GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Cambridge Nutritional Sciences plc in the live analysis
One click puts Cambridge Nutritional Sciences plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
